Table 1. Summary of the kinases activated by TRAIL in different tumor types.

Kinase	Tumor type	Response	Reference
IκB/NF-κB	Leukemia, neuroblastoma, pancreatic, mantle cell lymphoma, NSCLC	Pro-survival	39, 40, 41, 42, 43
	Glioma	Pro-apoptotic	38
JNK	Lymphoid, cholangiocarcinoma	Pro-apoptotic	47, 51
	Hepatocellular carcinoma	Pro-survival	54
Short JNK1	Colon	Pro-survival	56
Long JNK1	Colon	Pro-apoptotic	56
p38	Ovarian	Pro-apoptotic	57
	Prostate, breast	Pro-survival	59, 60
ERK	Colon, SCLC, melanoma, glioma	Proliferative	62, 63, 64, 65
TAK1	Prostate, ovarian	Pro-survival	59, 68
PKC	Pancreatic	Pro-survival	70
δ, ɛ, η	Melanoma, breast	Pro-survival	71, 72
α, β, γ	NSCLC	Pro-apoptotic	75
PI3K/Akt	Leukemia, ovarian, breast, NSCLC, prostate	Pro-survival	77, 81, 82, 83
Src	Prostate, NSCLC, hepatic, breast	Migratory/invasive and pro-survival	80, 82, 86, 87

Abbreviations: ERK, extracellular regulated kinases; IκB, inhibitor of kβ JNK, c-Jun NH₂ terminal kinases; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NSCLC, non-small cell lung cancer; PI3K, Phosphatidylinositide 3-kinases; PKC, protein kinase; SCLC, small cell lung cancer; Src, Rous sarcoma oncogene cellular homolog; TAK1, transforming growth factor-β (TGF-β)-activated kinase 1

The functional consequences of activation being either pro-apoptotic, pro-survival, proliferative or migratory are indicated.